Merck Group

Merck Group, often referred to as Merck KGaA, is a leading German multinational science and technology company with a history tracing back to 1668. Headquartered in Darmstadt, it operates across the healthcare, life science, and electronics sectors, developing everything from innovative cancer therapies to essential materials for semiconductor manufacturing. The company is a constituent of the DAX stock index and maintains a significant global presence, distinct from the American pharmaceutical firm Merck & Co..

History

The company's origins date to 1668 when Friedrich Jacob Merck acquired the Engel-Apotheke (Angel Pharmacy) in Darmstadt. In the 19th century, under Heinrich Emanuel Merck, the business began the industrial-scale manufacture and wholesale of alkaloids, marking its transition from a pharmacy to a chemical-pharmaceutical manufacturer. A pivotal moment came in 1891 with the synthesis of morphine, solidifying its research reputation. The 20th century saw expansion into new areas, including the founding of Merck Serono and significant growth in liquid crystals for displays. A major corporate split occurred in 1917 when the US subsidiary was confiscated as enemy property during World War I, eventually becoming the independent Merck & Co.. The post-war era featured strategic acquisitions like Sigma-Aldrich in 2015, dramatically expanding its life science business.

Business segments

The company is organized into three main business sectors. The Healthcare sector focuses on innovative prescription medicines, with key therapeutic areas including oncology, immunology, and fertility. Prominent products include the cancer drug Bavencio (developed in partnership with Pfizer) and Mavenclad for multiple sclerosis. The Life Science sector provides a vast portfolio of tools, services, and products for scientific research, biopharmaceutical manufacturing, and testing, serving academic labs and companies like Moderna. The Electronics sector supplies high-tech materials essential for the semiconductor and display industry, such as photoresists for chip fabrication and liquid crystals for LCD screens.

Research and development

Research and development activities are central to its strategy, with major sites in Darmstadt, Boston, and Tokyo. The company invests heavily in discovering and developing new medicines, particularly in oncology, with a pipeline targeting pathways like AKT inhibition. In Life Science, R&D focuses on advancing areas like genome editing with CRISPR technologies and bioprocessing for cell and gene therapies. The Electronics unit drives innovation in material science to meet the demands of next-generation microchips and OLED displays. Collaborations with academic institutions, the Broad Institute, and industry partners are a key component of its open innovation model.

Corporate affairs

The company is structured as a KGaA (Kommanditgesellschaft auf Aktien), with the Merck family holding a majority of the partnership shares through E. Merck KG. It is listed on the Frankfurt Stock Exchange and is a member of the DAX 40. Global operations are managed from Darmstadt, with significant regional hubs in the United States, China, and Japan. Leadership is provided by the Executive Board, chaired by CEO Belén Garijo, under the supervision of the Supervisory Board chaired by Johannes Baillou. The firm actively promotes sustainability initiatives, aiming for carbon-neutral production by 2040, and supports educational programs through the Merck Foundation.

Controversies

The company has faced several controversies over its long history. During the Nazi era, the business was implicated through its involvement with the IG Farben conglomerate and the use of forced labor at its facilities. In the 1950s, it was involved in distributing the drug Thalidomide in some markets, which later caused widespread birth defects. More recently, the 2017 acquisition of Versum Materials was challenged by US regulators on antitrust grounds before ultimately proceeding. The Healthcare sector has also navigated patent disputes and litigation, including cases related to its multiple sclerosis treatments, with settlements reached with companies like Mylan.

Category:Pharmaceutical companies of Germany Category:Companies listed on the Frankfurt Stock Exchange Category:DAX Category:Companies established in 1668 Category:Darmstadt